Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. MYND Lifesciencs Inc.
  6. News
  7. Summary
    MYND   CA62857B1094

MYND LIFESCIENCS INC.

(MYND)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary - MYND Diagnostics Ltd

10/07/2021 | 06:58am EST

MYND Life Sciences Inc. announced the formation of its diagnostic biomarker division with the incorporation of a wholly-owned subsidiary, MYND Diagnostics Ltd. ("MYND Diagnostics" or the "Subsidiary"). MYND Diagnostics' robust investigational pipeline of diagnostics, novel small molecules, and biologics, is focused on improving disease outcomes, monitoring and improving the treatment experience for patients suffering from Major Depressive Disorder ("MDD"), Treatment Resistant Depression ("TRD") and other inflammatory afflictions of the Central Nervous System. The Subsidiary's innovation, enabled by proprietary technology, allows for the quantitative and qualitative measurement of the MYND Anti-inflammatory Peptide ("MAP") biomarker. The subsidiary forecasts revenue by Second Quarter of 2022.


ę S&P Capital IQ 2021
All news about MYND LIFESCIENCS INC.
01/12MYND Lifesciencs Inc. Announces Resignation of Jordan Cleland as Chief Operating Office..
CI
01/12Mynd Life Sciences Announces Collaborative Research Agreement with the University of Br..
CI
2021MYND Lifesciencs Inc. Provides Update on Depression Gene Modulation Pathway Patent Appl..
CI
2021MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation
AQ
2021MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test
AQ
2021MYND Diagnostics Inc. Commences Clinical Research on Multiple Sclerosis Biomarker Test
CI
2021MYND Lifesciencs Inc. Announces Board and Audit Committee Changes
CI
2021MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Tre..
CI
2021KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Vie..
AQ
2021KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -0,00 M -0,00 M -0,00 M
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 8,39 M 6,62 M 6,64 M
Capi. / Sales 2019 -
Capi. / Sales 2020 -
Nbr of Employees 10
Free-Float -
Chart MYND LIFESCIENCS INC.
Duration : Period :
MYND Lifesciencs Inc. Technical Analysis Chart | MYND | CA62857B1094 | MarketScreener
Income Statement Evolution
Managers and Directors
Lyle Oberg Chief Executive Officer & Director
Paul Ciullo Chief Financial Officer & Secretary
Wilfred A. Jefferies Chairman & Chief Science Officer
John Campbell Independent Director
Roslyn Ritchie-Derrien Independent Director